Key facts
- Numan’s last known valuation is $200.7M (Jul 2021).
- It has raised $86.4M; the latest was Accelerator/Incubator ($71.0M) in Mar 2026.
- Notable investors include Tech Nation Group, Endeavor Catalyst, Anthemis, White Star Capital, Endeavor Greece — 17 tracked in total.
- Status: Privately Held (backing).
Leadership
- Benjamin MillsDirector
- Fonzie CamposFounder
- Grigoris KouterisExecutive Officer
- James ParkerChief Financial Officer
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Numan
- ·The full record, as it builds
Funding rounds
No funding rounds for Numan are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Numan
Operator of a digital healthcare platform intended to address weight loss, erectile dysfunction and other health conditions. The company's platform promotes accessible medical remedies through a brand and storytelling around health issues affecting men's self-esteem and lifestyle choices by offering direct-to-consumer medical products, enabling patients to control the symptoms by looking for alternatives online.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2018
- Employees
- 486
- Website
- numan.com/
- Ownership
- Privately Held (backing)
Numan doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Numan shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Numan in its N-PORT filings yet. We sweep new filings monthly.